Modus Therapeutics Novel Drugs - Sickle Cell Disease
Modus Therapeutics AB is a clinical-stage drug development company that develops pharmaceutical therapies to restore impaired blood flow and oxygen transport in rare diseases with unmet medical need.
The company’s development portfolio includes sevuparin, a drug used to treat people suffering from sickle cell disease.
Its sevuparin drug holds the ability to restore blood flow during microvascular obstructions by exerting its anti-adhesive effects to treat inherited blood disorders and various malarial diseases. The company was founded in 2011 and is based in Stockholm, Sweden. Modus Therapeutics AB operates as a subsidiary of Dilafor AB.
Showcase to 300+ investors and pharma at our 5th flagship LSX World Congress.
Plus save £500 before 14th December!
LSX is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.